Acessibilidade / Reportar erro

Clinical and laboratory evaluation of barbexaclone in the treatment of epilepsy

Twenty nine patients were treated with barbexaclone for 6-41 months. Eighteen of these patients suffered from grand-mal epilepsy and complete control of the crises was achieved in 16 of them. No alterations were noted in the hemogram, liver or renal function tests. Side effects were minimal and didn't neccessitate discontinueing the drug. 25% of the patients also showed a psychological improvement on the medication.


Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org